BR112022018651A2 - Agonistas do receptor farnesoide x para o tratamento de doenças - Google Patents

Agonistas do receptor farnesoide x para o tratamento de doenças

Info

Publication number
BR112022018651A2
BR112022018651A2 BR112022018651A BR112022018651A BR112022018651A2 BR 112022018651 A2 BR112022018651 A2 BR 112022018651A2 BR 112022018651 A BR112022018651 A BR 112022018651A BR 112022018651 A BR112022018651 A BR 112022018651A BR 112022018651 A2 BR112022018651 A2 BR 112022018651A2
Authority
BR
Brazil
Prior art keywords
farnesoid
diseases
treatment
receptor agonists
agonists
Prior art date
Application number
BR112022018651A
Other languages
English (en)
Portuguese (pt)
Inventor
song Kenneth
Chen Hubert
Wagner Brandee
D Smith Nicholas
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of BR112022018651A2 publication Critical patent/BR112022018651A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022018651A 2020-03-18 2021-03-17 Agonistas do receptor farnesoide x para o tratamento de doenças BR112022018651A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US202163140735P 2021-01-22 2021-01-22
PCT/US2021/022786 WO2021188688A1 (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease

Publications (1)

Publication Number Publication Date
BR112022018651A2 true BR112022018651A2 (pt) 2022-11-29

Family

ID=77771857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018651A BR112022018651A2 (pt) 2020-03-18 2021-03-17 Agonistas do receptor farnesoide x para o tratamento de doenças

Country Status (12)

Country Link
US (1) US20230131804A1 (https=)
EP (1) EP4121048A4 (https=)
JP (1) JP7851856B2 (https=)
KR (1) KR20220154801A (https=)
CN (4) CN120732854A (https=)
AU (1) AU2021240001A1 (https=)
BR (1) BR112022018651A2 (https=)
CA (1) CA3172205A1 (https=)
IL (1) IL296539A (https=)
MX (1) MX2022011579A (https=)
TW (1) TWI895384B (https=)
WO (1) WO2021188688A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
IL296532A (en) 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP2018510866A (ja) * 2015-03-13 2018-04-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腸受容体を活性化させるための、ファルネソイドｘ受容体アゴニストでの、成体の潜在性自己免疫性糖尿病の治療
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
JP2018536016A (ja) * 2015-09-16 2018-12-06 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
WO2017049173A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
LT3609888T (lt) 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
IL269068B (en) * 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途

Also Published As

Publication number Publication date
WO2021188688A1 (en) 2021-09-23
TW202143961A (zh) 2021-12-01
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
TWI895384B (zh) 2025-09-01
JP2023518397A (ja) 2023-05-01
CA3172205A1 (en) 2021-09-23
MX2022011579A (es) 2022-11-30
CN115666559A (zh) 2023-01-31
CN120732856A (zh) 2025-10-03
KR20220154801A (ko) 2022-11-22
CN120732855A (zh) 2025-10-03
IL296539A (en) 2022-11-01
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
JP7851856B2 (ja) 2026-04-27
AU2021240001A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
BR112022018651A2 (pt) Agonistas do receptor farnesoide x para o tratamento de doenças
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
Toren et al. Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models
BR112022002723A2 (pt) Métodos de tratamento de transtornos psicológicos e do cérebro
MX2019006177A (es) Metodos para tratar afecciones inflamatorias.
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
BR112023016680A2 (pt) Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina
BR112018005163A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
CL2022001708A1 (es) Decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BR112019023820A2 (pt) moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel
BR112023003427A2 (pt) Terapia com antagonista de lag-3 para carcinoma hepatocelular
JOP20190040A1 (ar) توليفة من ناهضات fxr
BR112018012626A2 (pt) ccl20 como um preditor de resposta clínica a antagonistas de il23
PH12021550671A1 (en) Prodrugs of cgrp antagonists
BR112019024707A2 (pt) terapias antissenso para tratamento de câncer
BR112015029852A2 (pt) método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112022015608A2 (pt) Fetuína-a para o tratamento de transtornos renais
BR112022008610A2 (pt) Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ORGANOVO, INC. (US)

B25A Requested transfer of rights approved

Owner name: ELI LILLY AND COMPANY (US)